Invasive pneumococcal infections in pediatric liver-small bowel-pancreas transplant recipients

Hanh D. Vo, Diana F Florescu, Cindy R. Brown, Heather E. Chambers, David F Mercer, Luciano M Vargas, Wendy J. Grant, Alan Norman Langnas, Ruben Quiros

Research output: Contribution to journalArticle

Abstract

Children undergoing LSBPTx are at increased risk of IPI due to splenectomy. We aimed to describe the clinical features and outcomes of IPI in pediatric LSBPTx recipients. Between 2008 and 2016, 122 LSBPTx children at our center were retrospectively reviewed. Nine patients had 12 episodes of IPI; the median age at first infection was 3.5 years (range: 1.5-7.1 years). The median time from transplant to first infection was 3 years (range: 0.8-5.8 years). Clinical presentation included as follows: pneumonia (n = 1), bacteremia/sepsis (n = 7), pneumonia with sepsis (n = 1), meningitis with sepsis (n = 2), pneumonia and meningitis with sepsis (n = 1). The overall risk for IPI was 7.4% or 0.9% per year. The mortality rate was 22%. Seven (78%) children had received at least one dose of PCV13, four (44%) patients had received 23-valent pneumococcal polysaccharide vaccine prior to IPI. All patients were on oral penicillin prophylaxis. In conclusion, despite partial or complete pneumococcal immunization and reported antimicrobial prophylaxis, IPI in LSBPTx children can have a fatal outcome. Routine monitoring of pneumococcal serotype antibodies to determine the timing for revaccination might be warranted to ensure protective immunity in these transplant recipients.

Original languageEnglish (US)
Article numbere13165
JournalPediatric Transplantation
Volume22
Issue number3
DOIs
StatePublished - May 2018

Fingerprint

Pneumococcal Infections
Pancreas
Sepsis
Pediatrics
Pneumonia
Liver
Meningitis
Secondary Immunization
Pneumococcal Vaccines
Fatal Outcome
Splenectomy
Bacteremia
Infection
Penicillins
Immunity
Immunization
Transplants
Mortality
Transplant Recipients
Antibodies

Keywords

  • children
  • intestinal transplant
  • pneumococcal conjugate vaccine
  • pneumococcal infection
  • pneumococcal polysaccharide vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Invasive pneumococcal infections in pediatric liver-small bowel-pancreas transplant recipients. / Vo, Hanh D.; Florescu, Diana F; Brown, Cindy R.; Chambers, Heather E.; Mercer, David F; Vargas, Luciano M; Grant, Wendy J.; Langnas, Alan Norman; Quiros, Ruben.

In: Pediatric Transplantation, Vol. 22, No. 3, e13165, 05.2018.

Research output: Contribution to journalArticle

@article{68f7c1c54c9c41b7bd455fe4818a755a,
title = "Invasive pneumococcal infections in pediatric liver-small bowel-pancreas transplant recipients",
abstract = "Children undergoing LSBPTx are at increased risk of IPI due to splenectomy. We aimed to describe the clinical features and outcomes of IPI in pediatric LSBPTx recipients. Between 2008 and 2016, 122 LSBPTx children at our center were retrospectively reviewed. Nine patients had 12 episodes of IPI; the median age at first infection was 3.5 years (range: 1.5-7.1 years). The median time from transplant to first infection was 3 years (range: 0.8-5.8 years). Clinical presentation included as follows: pneumonia (n = 1), bacteremia/sepsis (n = 7), pneumonia with sepsis (n = 1), meningitis with sepsis (n = 2), pneumonia and meningitis with sepsis (n = 1). The overall risk for IPI was 7.4{\%} or 0.9{\%} per year. The mortality rate was 22{\%}. Seven (78{\%}) children had received at least one dose of PCV13, four (44{\%}) patients had received 23-valent pneumococcal polysaccharide vaccine prior to IPI. All patients were on oral penicillin prophylaxis. In conclusion, despite partial or complete pneumococcal immunization and reported antimicrobial prophylaxis, IPI in LSBPTx children can have a fatal outcome. Routine monitoring of pneumococcal serotype antibodies to determine the timing for revaccination might be warranted to ensure protective immunity in these transplant recipients.",
keywords = "children, intestinal transplant, pneumococcal conjugate vaccine, pneumococcal infection, pneumococcal polysaccharide vaccine",
author = "Vo, {Hanh D.} and Florescu, {Diana F} and Brown, {Cindy R.} and Chambers, {Heather E.} and Mercer, {David F} and Vargas, {Luciano M} and Grant, {Wendy J.} and Langnas, {Alan Norman} and Ruben Quiros",
year = "2018",
month = "5",
doi = "10.1111/petr.13165",
language = "English (US)",
volume = "22",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Invasive pneumococcal infections in pediatric liver-small bowel-pancreas transplant recipients

AU - Vo, Hanh D.

AU - Florescu, Diana F

AU - Brown, Cindy R.

AU - Chambers, Heather E.

AU - Mercer, David F

AU - Vargas, Luciano M

AU - Grant, Wendy J.

AU - Langnas, Alan Norman

AU - Quiros, Ruben

PY - 2018/5

Y1 - 2018/5

N2 - Children undergoing LSBPTx are at increased risk of IPI due to splenectomy. We aimed to describe the clinical features and outcomes of IPI in pediatric LSBPTx recipients. Between 2008 and 2016, 122 LSBPTx children at our center were retrospectively reviewed. Nine patients had 12 episodes of IPI; the median age at first infection was 3.5 years (range: 1.5-7.1 years). The median time from transplant to first infection was 3 years (range: 0.8-5.8 years). Clinical presentation included as follows: pneumonia (n = 1), bacteremia/sepsis (n = 7), pneumonia with sepsis (n = 1), meningitis with sepsis (n = 2), pneumonia and meningitis with sepsis (n = 1). The overall risk for IPI was 7.4% or 0.9% per year. The mortality rate was 22%. Seven (78%) children had received at least one dose of PCV13, four (44%) patients had received 23-valent pneumococcal polysaccharide vaccine prior to IPI. All patients were on oral penicillin prophylaxis. In conclusion, despite partial or complete pneumococcal immunization and reported antimicrobial prophylaxis, IPI in LSBPTx children can have a fatal outcome. Routine monitoring of pneumococcal serotype antibodies to determine the timing for revaccination might be warranted to ensure protective immunity in these transplant recipients.

AB - Children undergoing LSBPTx are at increased risk of IPI due to splenectomy. We aimed to describe the clinical features and outcomes of IPI in pediatric LSBPTx recipients. Between 2008 and 2016, 122 LSBPTx children at our center were retrospectively reviewed. Nine patients had 12 episodes of IPI; the median age at first infection was 3.5 years (range: 1.5-7.1 years). The median time from transplant to first infection was 3 years (range: 0.8-5.8 years). Clinical presentation included as follows: pneumonia (n = 1), bacteremia/sepsis (n = 7), pneumonia with sepsis (n = 1), meningitis with sepsis (n = 2), pneumonia and meningitis with sepsis (n = 1). The overall risk for IPI was 7.4% or 0.9% per year. The mortality rate was 22%. Seven (78%) children had received at least one dose of PCV13, four (44%) patients had received 23-valent pneumococcal polysaccharide vaccine prior to IPI. All patients were on oral penicillin prophylaxis. In conclusion, despite partial or complete pneumococcal immunization and reported antimicrobial prophylaxis, IPI in LSBPTx children can have a fatal outcome. Routine monitoring of pneumococcal serotype antibodies to determine the timing for revaccination might be warranted to ensure protective immunity in these transplant recipients.

KW - children

KW - intestinal transplant

KW - pneumococcal conjugate vaccine

KW - pneumococcal infection

KW - pneumococcal polysaccharide vaccine

UR - http://www.scopus.com/inward/record.url?scp=85045516660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045516660&partnerID=8YFLogxK

U2 - 10.1111/petr.13165

DO - 10.1111/petr.13165

M3 - Article

C2 - 29441651

AN - SCOPUS:85045516660

VL - 22

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 3

M1 - e13165

ER -